- Bora Pharmaceuticals acquires Emergent BioSolutions’ sterile manufacturing facility in Baltimore-Camden, Maryland.
- This acquisition expands Bora’s capabilities in sterile drug product manufacturing and complements its existing biologics services.
Bora Pharmaceuticals Co., Ltd. announced the acquisition of Emergent BioSolutions’ sterile manufacturing facility in Baltimore-Camden, Maryland. This move marks a significant step in Bora’s commercial expansion strategy in North America.
Earlier this year, Bora acquired Upsher-Smith Laboratories, a generics manufacturer in Minnesota. The new 87,000-square-foot facility in Baltimore will provide sterile injectables manufacturing services, including clinical and commercial non-viral aseptic fill/finish services on four fill lines. These services will encompass lyophilization, vials filling, and pre-filled syringe filling.
Bora’s Chairman and CEO, Bobby Sheng, stated, “This transaction not only demonstrates our commitment to our growth strategy and plans for expansion in North America, but also enables us to expand our offering for our biologics customers. We look forward to working with the hugely talented team at the facility and supporting new and existing customers as we grow and develop the facility.”
The acquisition allows Bora to offer both drug substance and drug product capabilities, complementing the services of Bora Biologics. The sterile injectable market is projected to reach approximately $1.0 trillion by 2030, with a compound annual growth rate of 10.17%. Bora plans to enhance the newly acquired facility, retaining the current staff at the Camden site.
Overview of outsourcing trends 
